ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

NCT06388031 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Immune checkpoint inhibitor

Sponsor

Peking Union Medical College Hospital